<p>Sheets Smith Investment Management 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度收购了 Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）的新股份。该基金收购了 132,904 股公司股票，价值约 946,000 美元。Sheets Smith Investment Management 在最近的报告期末持有 Journey Medical 约 0.51% 的股份。</p>
<p>获取 <strong>Journey Medical</strong> 警报：</p>
<p>其他几家机构投资者和对冲基金最近也对该公司的持仓进行了调整。Titleist Asset Management LLC 在第一季度将其在 Journey Medical 的持股增加了 18.3%。Titleist Asset Management LLC 目前持有 12,900 股公司股票，价值 76,000 美元，此前在该期间内又收购了 2,000 股。新泽西州警察和消防员退休系统在第二季度购买了 Journey Medical 的新股份，价值约 29,000 美元。美国银行（Bank of America Corp DE）在第二季度将其在 Journey Medical 的持股增加了 4,707.0%。美国银行（Bank of America Corp DE）目前持有 4,134 股公司股票，价值 30,000 美元，此前在该期间内又购买了 4,048 股。Raymond James Financial Inc. 在第二季度购买了 Journey Medical 的新股份，价值 36,000 美元。最后，Pale Fire Capital SE 在第二季度将其在 Journey Medical 的持仓增加了 19.0%。Pale Fire Capital SE 目前持有 32,458 股公司股票，价值 233,000 美元，此前在该期间内又购买了 5,184 股。机构投资者持有公司 7.25% 的股份。</p>
<h2>Journey Medical 股票上涨 2.1%</h2>
<p>DERM 股票周五开盘价为 7.92 美元。该公司的市值为 2.1495 亿美元，市盈率为 -22.63，贝塔值为 0.80。公司的 50 日移动平均价格为 7.90 美元，200 日移动平均价格为 7.44 美元。Journey Medical Corporation 的 52 周低点为 3.54 美元，52 周高点为 9.40 美元。该公司的债务与股本比率为 0.75，速动比率为 1.12，流动比率为 1.42。</p>
<p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近在 11 月 12 日（星期三）公布了季度财报。该公司报告季度每股收益（EPS）为（0.09）美元，低于分析师一致预期的（0.08）美元，差额为（0.01）美元。该季度的营业收入为 1763 万美元，而分析师预期为 1885 万美元。Journey Medical 的净利润率为 -14.58%，股本回报率为 -39.94%。平均而言，股票研究分析师预计 Journey Medical Corporation 本财年将发布 -1.02 的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商最近对 DERM 进行了评估。HC Wainwright 在 8 月 25 日的研究报告中开始覆盖 Journey Medical。他们给予该公司 &#34;买入&#34; 评级，目标价为 13.00 美元。Zacks Research 在 10 月 13 日的报告中将 Journey Medical 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Journey Medical 的 &#34;卖出（d-）&#34; 评级。三位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;持有&#34;，平均目标价为 12.17 美元。</p>
<p><strong>阅读我们对 DERM 的最新分析</strong></p>
<h2>Journey Medical 公司简介</h2>
<p>（免费报告）</p>
<p>Journey Medical Corporation 专注于开发和商业化用于治疗美国皮肤病的药品。该公司的市场产品包括 Qbrexza，一种用于治疗原发性腋下多汗症的药用湿巾；Accutane，一种用于治疗严重顽固性结节性痤疮的口服异维 A 酸药物；以及 Amzeeq，一种用于治疗中度至重度非结节性痤疮炎症病变的米诺环素外用制剂。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Journey Medical 更好</li>
<li>大型股定义及如何投资</li>
<li>博通股票暴跌 20%——但华尔街认为其将飙升至 500 美元</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>MongoDB 可能会创下新高——但你需要迅速行动</li>
</ul>
<p><strong>想看看其他对冲基金持有 DERM 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Journey Medical 吗？</h2>
<p>在你考虑 Journey Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而 Journey Medical 并不在名单上。</p>
<p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

DERM

<p>Sheets Smith Investment Management 在第三季度收购了 132,904 股 Journey Medical Corporation，价值约为 946,000 美元。这笔收购代表了该公司约 0.51% 的股份。其他机构投资者也对 Journey Medical 的持仓进行了调整。该公司的股票开盘价为 7.92 美元，市值为 2.1495 亿美元。分析师对该股票的评级不一，普遍评级为 “持有”，平均目标价为 12.17 美元</p>

<p>Sheets Smith Investment Management acquired a new position in shares of Journey Medical Corporation (NASDAQ:DERM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 132,904 shares of the company's stock, valued at approximately $946,000. Sheets Smith Investment Management owned approximately 0.51% of Journey Medical at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Sheets Smith Investment Management 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度收购了 Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）的新股份。该基金收购了 132,904 股公司股票，价值约 946,000 美元。Sheets Smith Investment Management 在最近的报告期末持有 Journey Medical 约 0.51% 的股份。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Journey Medical</strong> 警报：</p>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Titleist Asset Management LLC lifted its holdings in Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period. Police &amp; Firemen s Retirement System of New Jersey purchased a new position in shares of Journey Medical during the 2nd quarter worth about $29,000. Bank of America Corp DE raised its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock worth $30,000 after buying an additional 4,048 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Journey Medical during the second quarter worth $36,000. Finally, Pale Fire Capital SE boosted its position in Journey Medical by 19.0% in the 2nd quarter. Pale Fire Capital SE now owns 32,458 shares of the company's stock valued at $233,000 after buying an additional 5,184 shares during the period. Institutional investors own 7.25% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对该公司的持仓进行了调整。Titleist Asset Management LLC 在第一季度将其在 Journey Medical 的持股增加了 18.3%。Titleist Asset Management LLC 目前持有 12,900 股公司股票，价值 76,000 美元，此前在该期间内又收购了 2,000 股。新泽西州警察和消防员退休系统在第二季度购买了 Journey Medical 的新股份，价值约 29,000 美元。美国银行（Bank of America Corp DE）在第二季度将其在 Journey Medical 的持股增加了 4,707.0%。美国银行（Bank of America Corp DE）目前持有 4,134 股公司股票，价值 30,000 美元，此前在该期间内又购买了 4,048 股。Raymond James Financial Inc. 在第二季度购买了 Journey Medical 的新股份，价值 36,000 美元。最后，Pale Fire Capital SE 在第二季度将其在 Journey Medical 的持仓增加了 19.0%。Pale Fire Capital SE 目前持有 32,458 股公司股票，价值 233,000 美元，此前在该期间内又购买了 5,184 股。机构投资者持有公司 7.25% 的股份。</p>
</div><h2>Journey Medical Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Journey Medical 股票上涨 2.1%</h2>
</div><p>DERM stock opened at $7.92 on Friday. The firm has a market capitalization of $214.95 million, a price-to-earnings ratio of -22.63 and a beta of 0.80. The company's 50 day moving average price is $7.90 and its 200 day moving average price is $7.44. Journey Medical Corporation has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42.</p>
<div class="lb-trans"><p>DERM 股票周五开盘价为 7.92 美元。该公司的市值为 2.1495 亿美元，市盈率为 -22.63，贝塔值为 0.80。公司的 50 日移动平均价格为 7.90 美元，200 日移动平均价格为 7.44 美元。Journey Medical Corporation 的 52 周低点为 3.54 美元，52 周高点为 9.40 美元。该公司的债务与股本比率为 0.75，速动比率为 1.12，流动比率为 1.42。</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The business had revenue of $17.63 million during the quarter, compared to analyst estimates of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%. On average, equities research analysts anticipate that Journey Medical Corporation will post -1.02 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近在 11 月 12 日（星期三）公布了季度财报。该公司报告季度每股收益（EPS）为（0.09）美元，低于分析师一致预期的（0.08）美元，差额为（0.01）美元。该季度的营业收入为 1763 万美元，而分析师预期为 1885 万美元。Journey Medical 的净利润率为 -14.58%，股本回报率为 -39.94%。平均而言，股票研究分析师预计 Journey Medical Corporation 本财年将发布 -1.02 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages recently weighed in on DERM. HC Wainwright started coverage on Journey Medical in a research note on Monday, August 25th. They set a &#34;buy&#34; rating and a $13.00 price objective for the company. Zacks Research raised shares of Journey Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $12.17.</p>
<div class="lb-trans"><p>多家券商最近对 DERM 进行了评估。HC Wainwright 在 8 月 25 日的研究报告中开始覆盖 Journey Medical。他们给予该公司 &#34;买入&#34; 评级，目标价为 13.00 美元。Zacks Research 在 10 月 13 日的报告中将 Journey Medical 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Journey Medical 的 &#34;卖出（d-）&#34; 评级。三位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;持有&#34;，平均目标价为 12.17 美元。</p>
</div><p><strong>Read Our Latest Analysis on DERM</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 DERM 的最新分析</strong></p>
</div><h2>Journey Medical Profile</h2>
<div class="lb-trans"><h2>Journey Medical 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</p>
<div class="lb-trans"><p>Journey Medical Corporation 专注于开发和商业化用于治疗美国皮肤病的药品。该公司的市场产品包括 Qbrexza，一种用于治疗原发性腋下多汗症的药用湿巾；Accutane，一种用于治疗严重顽固性结节性痤疮的口服异维 A 酸药物；以及 Amzeeq，一种用于治疗中度至重度非结节性痤疮炎症病变的米诺环素外用制剂。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Journey Medical 更好</li>
<li>大型股定义及如何投资</li>
<li>博通股票暴跌 20%——但华尔街认为其将飙升至 500 美元</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>MongoDB 可能会创下新高——但你需要迅速行动</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DERM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Journey Medical Corporation (NASDAQ:DERM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 DERM 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Journey Medical 吗？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Journey Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而 Journey Medical 并不在名单上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sheets Smith 投资管理公司向 Journey Medical Corporation $DERM 投资了 946,000 美元